The switch from CBZ to lacosamide as adjunctive therapy to LEV was well-tolerated.
Serum reproductive, thyroid, and lipid parameters were normalized at 8 weeks.
Antiseizure efficacy appeared to be maintained.
Further studies could confirm clinical utility.